Last reviewed 2026-04-20 · How we verify

Lithostat (ACETOHYDROXAMIC ACID)

Lithostat, also known as Acetohydroxamic acid, is a small molecule urease inhibitor developed by Mission Pharma. It targets carbonic anhydrase 2 and is used to treat Struvite Renal Calculi and Urinary tract infectious diseases. Lithostat was FDA approved in 1983 and is currently owned by Mission Pharma. It has a bioavailability of 55% but lacks generic manufacturers due to its off-patent status. As an off-patent medication, Lithostat's commercial status is no longer patented.

At a glance

Approved indications

• Struvite Renal Calculi
• Urinary tract infectious disease

Common side effects

• Headaches
• Gastrointestinal symptoms
• Nausea
• Vomiting
• Anorexia
• Malaise
• Hemolytic anemia
• Reticulocytosis
• Tremulousness
• Nervousness
• Depression
• Anxiety

Key clinical trials

• Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (PHASE2)
• MyHeart Counts Cardiovascular Health Study (NA)
• Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults (NA)
• Manipulating the Gut Microbiome Study (PHASE1,PHASE2)
• Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lithostat CI brief — competitive landscape report
• Lithostat updates RSS · CI watch RSS
• Mission Pharma portfolio CI